Compare COP & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COP | VRTX |
|---|---|---|
| Founded | 1917 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | EDP Services |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.5B | 115.7B |
| IPO Year | 2005 | 2006 |
| Metric | COP | VRTX |
|---|---|---|
| Price | $115.91 | $441.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 29 |
| Target Price | $123.59 | ★ $539.69 |
| AVG Volume (30 Days) | ★ 8.5M | 1.2M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | 6.35 | ★ 15.32 |
| Revenue | ★ $58,944,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | $6.88 | $10.81 |
| Revenue Next Year | N/A | $10.41 |
| P/E Ratio | ★ $19.12 | $28.46 |
| Revenue Growth | 7.67 | ★ 46.20 |
| 52 Week Low | $84.28 | $362.50 |
| 52 Week High | $135.87 | $510.77 |
| Indicator | COP | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.24 | 45.77 |
| Support Level | $89.51 | $427.52 |
| Resistance Level | $122.50 | $442.22 |
| Average True Range (ATR) | 3.91 | 10.31 |
| MACD | -2.01 | 0.72 |
| Stochastic Oscillator | 16.02 | 57.31 |
ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.